{"id":"NCT02213263","sponsor":"Pfizer","briefTitle":"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera速 (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-30","primaryCompletion":"2017-10-23","completion":"2018-04-19","firstPosted":"2014-08-11","resultsPosted":"2018-10-30","lastUpdate":"2019-06-20"},"enrollment":394,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Follicular Lymphoma"],"interventions":[{"type":"BIOLOGICAL","name":"PF-05280586","otherNames":[]},{"type":"BIOLOGICAL","name":"MabThera速","otherNames":[]}],"arms":[{"label":"PF-05280586","type":"EXPERIMENTAL"},{"label":"MabThera速","type":"ACTIVE_COMPARATOR"}],"summary":"This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.","primaryOutcome":{"measure":"Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"Rituximab-EU","deltaMin":70.7,"sd":null},{"arm":"PF-05280586","deltaMin":75.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":423,"countries":["United States","Austria","Belarus","Belgium","Brazil","Croatia","France","Georgia","Germany","Greece","India","Italy","Japan","Lebanon","Mexico","Peru","Philippines","Poland","Portugal","Puerto Rico","Romania","Russia","South Africa","South Korea","Spain","Switzerland","Thailand","Turkey (T端rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["34152584","31820339"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3281006"]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":197},"commonTop":["Infusion related reaction","Headache","Pruritus","Nausea","Diarrhoea"]}}